Express Scripts (ESRX), Medco (MHS) Deal Likely to Pass FTC Scrutiny

March 9, 2012 1:22 PM EST
Express Scripts (Nasdaq: ESRX) is moving higher following a recent pop as the WSJ is reporting that the Federal Trade Commission (FTC) is unlikely to block its proposed merger with Medco Health (NYSE: MHS).

Though the FTC is said to still have concerns, people in the know told the WSJ that talks are currently going on to resolve the issues. Further, the FTC isn't gathering evidence or witness statements to file an antitrust case against the deal, amid requests to do so by several trade and consumer groups.

The FTC did not comment on the story and reps from Express Scripts and Medco have said they expect the $29 billion deal to close within the first half of 2012. Express Scripts is up over 2 percent while Medco is 1.9 percent better.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Mergers and Acquisitions, Rumors

Add Your Comment